Quick Answer
ImageneBio, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $800.0 thousand for the year ending 2025.
- ImageneBio, Inc. showed a decrease of -77.1% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from ImageneBio, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $3.23 million | Q2 2020: $3.07 million | Q3 2020: $2.83 million | Q1 2021: $3.47 million | Q2 2021: $3.55 million | Q3 2021: $3.75 million | Q1 2022: $3.38 million | Q2 2022: $382.0 thousand | Q3 2022: $6.40 million | Q1 2023: $5.31 million | Q2 2023: $2.00 million | Q3 2023: $1.19 million | Q3 2024: $3.50 million.
- Over the full 6 years of available data (2020 to 2025), ImageneBio, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 91.3%.
- Historical annual values: Fiscal year 2025: $800.0 thousand | Fiscal year 2024: $3.50 million | Fiscal year 2023: $9.16 million | Fiscal year 2022: $15.62 million | Fiscal year 2021: $30.99 million | Fiscal year 2020: $9.19 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: